Telis Bioscience develops protein therapeutics using automated workflows to accelerate the transition from molecular design to clinical trials. The company addresses the lengthy drug development process, enabling faster delivery of new medicines to patients and the market.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ARFounders
Product
Problem
Traditional drug development is a lengthy process, often taking many years to transition from initial molecular design to clinical trials, which delays the delivery of new medicines to patients. This slow pace can hinder the response to emerging health crises and limit the impact of biotechnology advancements.
Solution
Alvea aimed to accelerate drug development by automating and re-engineering rate-limiting workflows, thereby reducing the time from molecule to clinical trials. The company focused on in-housing key processes and working with partners at the cutting edge of drug design and discovery. By optimizing the development pipeline, Alvea sought to deliver new medicines to patients and the market more rapidly, particularly for pandemic response and other critical health needs.
Target Audience
Alvea targeted biotechnology companies and organizations involved in drug design and discovery, particularly those focused on pandemic preparedness and rapid response to emerging health threats.
Features
- Automated workflows for rapid drug development
- Focus on in-housing and re-engineering rate-limiting steps
- Expertise in plasmid DNA vaccine development
- Streamlined process from initial concept to Phase 1 clinical trials